MCV

(redirected from Meningococcal Conjugate Vaccine)
AcronymDefinition
MCVMean Corpuscular Volume
MCVMobile Car Valeting (UK and Ireland)
MCVMedical College of Virginia
MCVModel Controller View (programming)
MCVMutated Citrullinated Vimentin (immunology)
MCVMaladies Cardio Vasculaires (French: Cardiovascular Disease)
MCVMean Cell Volume
MCVMedium Commercial Vehicle
MCVMulti Convivial Vehicle
MCVModeling Clipping Volume
MCVMissing Control Variable
MCVMeasles-Containing Vaccine
MCVMid-Cap Value (finance)
MCVMountainbike Club Vejle (Danish biking club)
MCVMeningococcal Conjugate Vaccine
MCVModel View Controller
MCVMulti Convivial Vehicle (Dacia car)
MCVMidland Cogeneration Venture (Midland, Michigan)
MCVMobile Construction Vehicle
MCVMesoscale Convective Vortex
MCVMainzer Carneval Verein (German: Mainz Carnival Club)
MCVmaritime crew visa
MCVMiddlesex County Volunteers Fifes and Drums (est. 1982; Massachusetts)
MCVMcConnell Valdes (legal partnership in Puerto Rico)
MCVMobile Coordinating Vehicle (US FEMA)
MCVMerck Capital Ventures, LLC (investment)
MCVMain Control Valve
MCVMultipoint Command Visualization
MCVMilitary College of Vermont
MCVMotorized Control Valve
MCVMoto-Club Villeneuvois (French motorcycle club)
MCVMulluscum Contagiosum Virus
MCVMission Critical Variant (test and evaluation)
MCVMeningitis Conjugated Vaccine
MCVMunitions Clearance Vehicle
MCVMaritiome Commission, Victory Ship (US Navy)
References in periodicals archive ?
Although neither meningococcal conjugate vaccine product is licensed for use in individuals 56 years or older, ACIP recommends using one of the products for HIVinfected individuals in this age group because the only meningococcal vaccine licensed for use in adults 56 or older, meningococcal polysaccharide vaccine (MPSV4, Menomune, Sanofi Pasteur), has not been studied in patients with HIV infection.
Recommendations for use of meningococcal conjugate vaccines in HIV-infected persons--Advisory Committee on Immunization Practices, 2016.
Researchers set out to evaluate the safety of one quadrivalent meningococcal conjugate vaccine, MenACWY-CRM.
Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013.
(7) An increasing number of jurisdictions have substituted the quadrivalent meningococcal conjugate vaccine for the meningococcal C conjugate vaccine for the pre-adolescent/adolescent booster dose.
meningitidis bacteria that cause meningococcal disease (A, C, W, and Y): They are the meningococcal polysaccharide vaccine (Menomune) and the meningococcal conjugate vaccine (Menactra and Menveo).
The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) has voted recently to recommend (13 Yes, 1 No, 1 Abstain) the meningococcal conjugate vaccine MenACWY-CRM ( Menveo, Novartis Vaccines) for use in infants and young toddlers who are at increased risk for meningococcal disease.
They focused on three vaccines routinely given in adolescence: Tdap, which guards against tetanus, diphtheria, and acellular pertussis; the meningococcal conjugate vaccine, or MCV4; and the vaccine that protects against HPV.
Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease.
M2 EQUITYBITES-December 4, 2012-Sanofi Pasteur Canada announces approval by Health Canada of Menactra Meningococcal Conjugate Vaccine for infants from nine months(C)2012 M2 COMMUNICATIONS http://www.m2.com
Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006.
Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA.